5-HT2A/2C receptor

Assets acting on this target.

Class
5-HT2A/2C inverse agonist

The 5-HT2A and 5-HT2C receptors are subtypes of the serotonin (5-hydroxytryptamine) receptor family, G-protein-coupled receptors expressed widely in the cortex, especially in regions governing sensory processing and mood. Serotonin signaling through these receptors modulates cortical excitability and is implicated in the neurobiology of psychosis and hallucinatory phenomena. Unlike many receptors that require a bound ligand to signal, 5-HT2A/2C receptors show measurable activity even without serotonin present, a property called constitutive activity. An inverse agonist binds the receptor and actively suppresses this baseline signaling, going beyond simply blocking serotonin's effects. This approach is of particular interest in treating psychosis associated with neurodegenerative conditions, where the dopamine-blocking antipsychotics conventionally used can worsen motor symptoms by further impairing an already compromised dopaminergic system. By acting through serotonin receptors rather than dopamine receptors, 5-HT2A/2C inverse agonism offers a route to reducing hallucinations and delusions without directly interfering with movement-related dopamine pathways. The dual 2A/2C profile reflects the overlapping but distinct roles of these subtypes in perception and mood regulation, aiming for broader antipsychotic-like efficacy than targeting either receptor alone.

Related mechanisms

5-HT2A/2C receptor drugs compared

2 drugs, stage by indication
2 drugs acting on 5-HT2A/2C receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
PimavanserinNuplazidAcadia Pharmaceuticalssmall moleculeApprovedApproved in Parkinson's Disease Psychosis
LY03017Luye Pharma Groupsmall moleculePhase 2Phase 1 in Alzheimer's Disease; Phase 1 in Parkinson's Disease; Phase 1 in Schizophrenia

← all mechanisms